A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the ...

This was the stock's second consecutive day of gains.

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.